Loading...

UCSF Coronavirus Response: UCSF is partnering with public agencies to address the rapidly evolving outbreak and protect our communities. The UCSF COVID-19 Resources Website provides guidance and information for our patients, faculty, staff, trainees and learners.

Jeroen Jansen, PhD

Title(s)Associate Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
ORCID ORCID Icon0000-0003-2686-9217 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Erasmus University, Rotterdam, NetherlandsPhD12/2004Epidemiology

    Collapse Overview 
    Collapse Overview
    Jeroen is a methodologist working at the intersection of evidence synthesis, biostatistics, and health economics.

    His current research interests are network meta-analysis and simulation modeling to understand the value of health care interventions, in particular related to oncology and precision medicine. Jeroen has performed applied and methods research in his areas of expertise. Notable contributions are the development of synthesis methods to overcome the typical challenges in cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. He is a co-author of a textbook on network meta-analysis for decision-making.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Cope S, Toor K, Popoff E, Fonseca R, Landgren O, Mateos MV, Weisel K, Jansen JP. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. Value Health. 2020 Apr; 23(4):441-450. PMID: 32327161.
      View in: PubMed
    2. Cope S, Chan K, Jansen JP. Multivariate Network Meta-Analysis Of Survival Function Parameters. Res Synth Methods. 2020 Mar 03. PMID: 32125077.
      View in: PubMed
    3. Sussell J, Silverstein AR, Goutam P, Incerti D, Kee R, Chen CX, Batty DS, Jansen JP, Kasiske BL. The economic burden of kidney graft failure in the United States. Am J Transplant. 2020 Feb 04. PMID: 32020739.
      View in: PubMed
    4. Jansen JP, Incerti D, Linthicum MT. Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project. Pharmacoeconomics. 2019 11; 37(11):1313-1320. PMID: 31392665.
      View in: PubMed
    5. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8. Adv Ther. 2019 11; 36(11):2982-2985. PMID: 31512141.
      View in: PubMed
    6. Cope S, Ayers D, Zhang J, Batt K, Jansen JP. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019 09 02; 19(1):182. PMID: 31477025.
      View in: PubMed
    7. Cope S, Keeping ST, Goldgrub R, Ayers D, Jansen JP, Penrod JR, Korytowsky B, Juarez-Garcia A, Yuan Y. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. J Comp Eff Res. 2019 Jul; 8(10):733-751. PMID: 31237143.
      View in: PubMed
    8. Berger KI, Kanters S, Jansen JP, Stewart A, Sparks S, Haack KA, Bolzani A, Siliman G, Hamed A. Forced vital capacity and cross-domain late-onset Pompe disease outcomes: an individual patient-level data meta-analysis. J Neurol. 2019 Sep; 266(9):2312-2321. PMID: 31187190.
      View in: PubMed
    9. Garrison LP, Jansen JP, Devlin NJ, Griffin S. Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. Value Health. 2019 06; 22(6S):S12-S17. PMID: 31200801.
      View in: PubMed
    10. Incerti D, Curtis JR, Shafrin J, Lakdawalla DN, Jansen JP. A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. Pharmacoeconomics. 2019 06; 37(6):829-843. PMID: 30737711.
      View in: PubMed
    11. Jansen JP, Incerti D, Curtis JR. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System. J Manag Care Spec Pharm. 2019 May; 25(5):518-521. PMID: 31039069.
      View in: PubMed
    12. Incerti D, Thom H, Baio G, Jansen JP. R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. Value Health. 2019 05; 22(5):575-579. PMID: 31104737.
      View in: PubMed
    13. Leahy J, Thom H, Jansen JP, Gray E, O'Leary A, White A, Walsh C. Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact. Stat Med. 2019 06 30; 38(14):2505-2523. PMID: 30895655.
      View in: PubMed
    14. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. Adv Ther. 2019 05; 36(5):1164-1176. PMID: 30879249.
      View in: PubMed
    15. Jansen JP, Khalid JM, Smyth MD, Patel H. The number needed to treat and relevant between-trial comparisons of competing interventions. Clinicoecon Outcomes Res. 2018; 10:865-871. PMID: 30588048.
      View in: PubMed
    16. Lorenzi M, Ambegaonkar B, Baxter CA, Jansen J, Zoratti MJ, Davies G. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol. 2019 May; 108(5):487-509. PMID: 30302558.
      View in: PubMed
    17. Shafrin J, Skornicki M, Brauer M, Villeneuve J, Lees M, Hertel N, Penrod JR, Jansen J. An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference? Health Policy. 2018 06; 122(6):607-613. PMID: 29731176.
      View in: PubMed
    18. Ericsson Å, Glah D, Lorenzi M, Jansen JP, Fridhammar A. Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. PLoS One. 2018; 13(2):e0191953. PMID: 29408938.
      View in: PubMed
    19. Evans M, Billings LK, Håkan-Bloch J, Slothuus U, Abrahamsen TJ, Andersen A, Jansen JP. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. J Med Econ. 2018 Apr; 21(4):340-347. PMID: 29164973.
      View in: PubMed
    20. Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Jul; 20(7):703-714. PMID: 28294642.
      View in: PubMed
    21. Jansen JP. Relevance of American Society of Clinical Oncology Value Framework Will Be Improved if It Is Based on Network Meta-Analyses. J Clin Oncol. 2017 04 01; 35(10):1131-1132. PMID: 28165901.
      View in: PubMed
    22. Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, Jansen JP. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017 Jun; 20(6):555-564. PMID: 28097904.
      View in: PubMed
    23. Druyts E, Palmer JB, Balijepalli C, Chan K, Fazeli MS, Herrera V, Jansen JP, Park JJH, Kanters S, Reimold A. Treatment modifying factors of biologics for psoriatic arthritis: a systematic review and Bayesian meta-regression. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):681-688. PMID: 28094756.
      View in: PubMed
    24. Lorenzi M, Ploug UJ, Langer J, Skovgaard R, Zoratti M, Jansen J. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis. Diabetes Ther. 2017 Feb; 8(1):85-99. PMID: 27995594.
      View in: PubMed
    25. Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis. Clin Ther. 2016 Dec; 38(12):2628-2641.e5. PMID: 27889300.
      View in: PubMed
    26. Jansen JP, Vieira MC, Bradley JD, Cappelleri JC, Zwillich SH, Wallenstein GV. Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2016 08 18; 17(1):348. PMID: 27538585.
      View in: PubMed
    27. Broekhuizen H, Groothuis-Oudshoorn CG, Hauber AB, Jansen JP, IJzerman MJ. Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. BMC Med Inform Decis Mak. 2015 Dec 02; 15:102. PMID: 26626279.
      View in: PubMed
    28. Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E. Erratum to: A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly. Infect Dis Ther. 2015 Dec; 4(4):489-90. PMID: 26407566.
      View in: PubMed
    29. Szabo SM, Hedegaard M, Chan K, Thorlund K, Christensen R, Vorum H, Jansen JP. Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. Curr Med Res Opin. 2015 Nov; 31(11):2031-42. PMID: 26296050.
      View in: PubMed
    30. Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly. Infect Dis Ther. 2015 Dec; 4(4):459-87. PMID: 26350238.
      View in: PubMed
    31. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 02; 162(11):777-84. PMID: 26030634.
      View in: PubMed
    32. Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. J Manag Care Spec Pharm. 2015 May; 21(5):409-23. PMID: 25943002.
      View in: PubMed
    33. Jansen JP, Vieira MC, Cope S. Network meta-analysis of longitudinal data using fractional polynomials. Stat Med. 2015 Jul 10; 34(15):2294-311. PMID: 25877808.
      View in: PubMed
    34. Toor K, Druyts E, Jansen JP, Thorlund K. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ. 2015 Jun; 18(6):437-46. PMID: 25629655.
      View in: PubMed
    35. Cope S, Clemens A, Hammès F, Noack H, Jansen JP. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials. Value Health. 2015 Mar; 18(2):234-49. PMID: 25773559.
      View in: PubMed
    36. Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to diagnose lung cancer. JAMA. 2015 Jan 27; 313(4):419. PMID: 25626041.
      View in: PubMed
    37. Thorlund K, Druyts E, Toor K, Jansen JP, Mills EJ. Incorporating alternative design clinical trials in network meta-analyses. Clin Epidemiol. 2015; 7:29-35. PMID: 25565891.
      View in: PubMed
    38. Johnston BC, Kanters S, Bandayrel K, Wu P, Naji F, Siemieniuk RA, Ball GD, Busse JW, Thorlund K, Guyatt G, Jansen JP, Mills EJ. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA. 2014 Sep 03; 312(9):923-33. PMID: 25182101.
      View in: PubMed
    39. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014 Jul 03; 12:102. PMID: 24988902.
      View in: PubMed
    40. Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014 Jun 05; 12:93. PMID: 24898705.
      View in: PubMed
    41. Ellis AG, Reginster JY, Luo X, Cappelleri JC, Chines A, Sutradhar S, Jansen JP. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis. Value Health. 2014 Jun; 17(4):424-32. PMID: 24969003.
      View in: PubMed
    42. Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP. Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women. Curr Med Res Opin. 2014 Aug; 30(8):1617-26. PMID: 24773456.
      View in: PubMed
    43. Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R, Salanti G. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar; 17(2):157-73. PMID: 24636374.
      View in: PubMed
    44. Cope S, Jansen JP. Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol. 2013 Dec 01; 13:147. PMID: 24289277.
      View in: PubMed
    45. Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, Buckley F, Ellis A, Jones P. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013 Oct 07; 14:100. PMID: 24093477.
      View in: PubMed
    46. Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014 Apr; 47(4):772-785.e5. PMID: 23981487.
      View in: PubMed
    47. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013 Jul 04; 11:159. PMID: 23826681.
      View in: PubMed
    48. Cope S, Ouwens MJ, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013 Mar-Apr; 16(2):403-17. PMID: 23538193.
      View in: PubMed
    49. Jansen JP, Cope S. Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes. BMC Med Res Methodol. 2012 Oct 08; 12:152. PMID: 23043545.
      View in: PubMed
    50. Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist. 2012; 17(11):1376-85. PMID: 23024154.
      View in: PubMed
    51. Cope S, Kraemer M, Zhang J, Capkun-Niggli G, Jansen JP. Efficacy of indacaterol 75 µg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2012; 7:415-20. PMID: 22848154.
      View in: PubMed
    52. Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 µg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med. 2012 Jun 25; 12:29. PMID: 22732017.
      View in: PubMed
    53. Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J Cyst Fibros. 2012 Sep; 11(5):419-26. PMID: 22717535.
      View in: PubMed
    54. Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE. Economic outcomes of treatment for ureteral and renal stones: a systematic literature review. J Urol. 2012 Aug; 188(2):449-54. PMID: 22698623.
      View in: PubMed
    55. Franchini AJ, Dias S, Ades AE, Jansen JP, Welton NJ. Accounting for correlation in network meta-analysis with multi-arm trials. Res Synth Methods. 2012 Jun; 3(2):142-60. PMID: 26062087.
      View in: PubMed
    56. Jansen JP. Network meta-analysis of individual and aggregate level data. Res Synth Methods. 2012 Jun; 3(2):177-90. PMID: 26062089.
      View in: PubMed
    57. Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE. Treatment of ureteral and renal stones: a systematic review and meta-analysis of randomized, controlled trials. J Urol. 2012 Jul; 188(1):130-7. PMID: 22591962.
      View in: PubMed
    58. Jansen JP, Schmid CH, Salanti G. Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. J Clin Epidemiol. 2012 Jul; 65(7):798-807. PMID: 22521579.
      View in: PubMed
    59. Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison. Value Health. 2012 May; 15(3):524-33. PMID: 22583463.
      View in: PubMed
    60. Stam W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. Open Rheumatol J. 2012; 6:6-20. PMID: 22582102.
      View in: PubMed
    61. Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review. AIDS Res Hum Retroviruses. 2012 Jan; 28(1):36-48. PMID: 21902585.
      View in: PubMed
    62. Vieira MC, Kumar RN, Jansen JP. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison. HIV Clin Trials. 2011 Jul-Aug; 12(4):175-89. PMID: 22044854.
      View in: PubMed
    63. Jansen JP, Taylor SD. Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway. Int J Rheumatol. 2011; 2011:160326. PMID: 21772851.
      View in: PubMed
    64. Cope S, Capkun-Niggli G, Gale R, Jardim JR, Jansen JP. Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2011; 6:329-44. PMID: 21697997.
      View in: PubMed
    65. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011 Jun; 14(4):429-37. PMID: 21669367.
      View in: PubMed
    66. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011 Jun; 14(4):417-28. PMID: 21669366.
      View in: PubMed
    67. Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011 May 06; 11:61. PMID: 21548941.
      View in: PubMed
    68. Ouwens MJ, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2010 Jul; 1(3-4):258-71. PMID: 26061470.
      View in: PubMed
    69. Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011 Mar-Apr; 14(2):274-81. PMID: 21402296.
      View in: PubMed
    70. Naik S, Lundberg J, Kumar R, Sjolin J, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand J Infect Dis. 2011 Jul; 43(6-7):504-14. PMID: 21332286.
      View in: PubMed
    71. van de Kerkhof P, de Peuter R, Ryttov J, Jansen JP. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris. Curr Med Res Opin. 2011 Jan; 27(1):225-38. PMID: 21142833.
      View in: PubMed
    72. Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood). 2010 Oct; 29(10):1826-33. PMID: 20921482.
      View in: PubMed
    73. Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011 Feb; 40(4):275-84.e1-2. PMID: 20828791.
      View in: PubMed
    74. Jansen JP, O'Sullivan AK, Lugtenburg E, Span LF, Janssen JJ, Stam WB. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Ann Hematol. 2010 Sep; 89(9):919-26. PMID: 20383504.
      View in: PubMed
    75. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010 Jun; 39(6):425-41. PMID: 20223500.
      View in: PubMed
    76. Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics. 2010; 28(4):323-44. PMID: 20222755.
      View in: PubMed
    77. Parthan A, Posner MR, Brammer C, Beltran P, Jansen JP. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2009 Oct; 31(10):1255-62. PMID: 19731394.
      View in: PubMed
    78. Jansen JP, Bergman GJ, Huels J, Olson M. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin. 2009 Aug; 25(8):1861-8. PMID: 19530978.
      View in: PubMed
    79. Jansen JP, Kumar R, Carmeli Y. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance. Value Health. 2009 Mar-Apr; 12(2):234-44. PMID: 20667059.
      View in: PubMed
    80. Jansen JP, Kumar R, Carmeli Y. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK. Pharmacoeconomics. 2009; 27(12):1045-56. PMID: 19908928.
      View in: PubMed
    81. Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008 Dec; 81(6):467-74. PMID: 18754857.
      View in: PubMed
    82. Stam WB, Aversa F, Kumar RN, Jansen JP. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health. 2008 Sep-Oct; 11(5):830-41. PMID: 18494752.
      View in: PubMed
    83. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health. 2008 Sep-Oct; 11(5):956-64. PMID: 18489499.
      View in: PubMed
    84. Jansen JP, Gaugris S, Bergman G, Sen SS. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. Curr Med Res Opin. 2008 Mar; 24(3):671-84. PMID: 18221588.
      View in: PubMed
    85. Jansen JP, Pellissier J, Choy EH, Ostor A, Nash JT, Bacon P, Hunsche E. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. Curr Med Res Opin. 2007 Dec; 23(12):3069-78. PMID: 17971283.
      View in: PubMed
    86. Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007 Jun; 78(6):532-9. PMID: 17419744.
      View in: PubMed
    87. Burdorf A, Jansen JP. Predicting the long term course of low back pain and its consequences for sickness absence and associated work disability. Occup Environ Med. 2006 Aug; 63(8):522-9. PMID: 16849528.
      View in: PubMed
    88. Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006 Apr; 22(4):671-81. PMID: 16684428.
      View in: PubMed
    89. Jansen JP, Kern WV, Cornely OA, Karthaus M, Ruhnke M, Ullmann AJ, Resch A. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health. 2006 Jan-Feb; 9(1):12-23. PMID: 16441520.
      View in: PubMed
    90. Eriksen HR, Ihlebaek C, Jansen JP, Burdorf A. The relations between psychosocial factors at work and health status among workers in home care organizations. Int J Behav Med. 2006; 13(3):183-92. PMID: 17078768.
      View in: PubMed
    91. Jansen JP, Meis JF, Blijlevens NM, van't Wout JW. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin. 2005 Oct; 21(10):1535-46. PMID: 16238893.
      View in: PubMed
    92. Jansen JP, Morgenstern H, Burdorf A. Dose-response relations between occupational exposures to physical and psychosocial factors and the risk of low back pain. Occup Environ Med. 2004 Dec; 61(12):972-9. PMID: 15550602.
      View in: PubMed
    93. Jansen JP, Burdorf A. Effects of measurement strategy and statistical analysis on dose-response relations between physical workload and low back pain. Occup Environ Med. 2003 Dec; 60(12):942-7. PMID: 14634186.
      View in: PubMed
    94. Jansen JP, Burdorf A, Steyerberg E. A novel approach for evaluating level, frequency and duration of lumbar posture simultaneously during work. Scand J Work Environ Health. 2001 Dec; 27(6):373-80. PMID: 11800324.
      View in: PubMed